Market Overview:
The global CD antigen cancer therapy market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of CD antigen cancer therapy. Based on type, the global CD antigen cancer therapy market is segmented into monoclonal antibodies, antibody-drug-conjugates (ADCs), tri-functional and bi-specific T-cell engager antibodies (bTACEs), and other therapies. Monoclonal antibodies are expected to account for the largest share of this market in 2018. This can be attributed to their high efficacy and safety profile as well as growing demand for personalized medicine. ADCs are also expected to witness significant growth during the forecast period owing to their ability to specifically target tumor cells while sparing healthy cells. Based on application, hospitals are estimated to account for the largest share of this market in 2018 followed by clinics.
Product Definition:
CD antigen cancer therapy is a type of cancer treatment that uses substances that attach to cancer cells and kill them or stop them from growing. CD antigen cancer therapies are used to treat many types of cancers, including leukemia, lymphoma, and solid tumors.
Monoclonal Antibodies:
Monoclonal Antibodies, also known as Monoclonal antibodies or MoAb are a type of drug that is used to treat cancer. They are very specific immune response modifiers. There are two types of monoclonal antibody: Humanized and Non-humanized.
Antibody-Drug-Conjugates:
Antibody-drug conjugates (ADC) are a group of drugs that bind with an antibody attached to it. The ADC moiety binds with the target cell and the drug does not harm the surrounding cells. This allows for safer and more effective cancer treatment than traditional chemotherapy drugs, which often damage healthy tissues along with tumor cells.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. Other applications include research settings and industrial production. The other applications are expected to witness significant growth with the introduction of new products and ongoing clinical trials for CD19-targeting antibodies, which is anticipated to result in high product demand during the forecast period.
Hospitals were estimated to be the largest revenue generating segment owing to increasing product adoption across various hospitals worldwide for treating patients suffering from B cell malignancies such as lymphoma and myeloma as well as solid tumors such as breast cancer, Non-small Cell Lung Cancer (NSCLC), pancreatic cancer, melanoma skin tumor or Kaposi¢â‚¬â„¢s Sarcoma (KS) disease due to its ability of inducing a strong immune response against tumor cells leading to enhanced immunity against these diseases.
Regional Analysis:
North America dominated the global CD antigen cancer therapy market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. The increasing prevalence of cancer is also one of the major factors responsible for its large share. For instance, according to statistics published by American Cancer Society (ACS), it was estimated that 1,762,780 new cases were diagnosed in U.S during 2016 and this number is expected to reach 2,mud2108 with a growth rate of about 8% per year.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising investments by leading pharmaceutical companies for research & development activities and an increase in healthcare expenditure levels coupled with growing patient awareness levels regarding advanced treatment options available globally especially those pertaining antigens targeted by mAbs or ADC therapies).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for CD antigen cancer therapy market. According to World Health Organization (WHO), the number of new cases diagnosed with cancer every year is estimated to be around 14 million and it is expected to rise by 70% in next two decades. This will create huge demand for CD antigen cancer therapies and boost the growth of this market.
- Rising awareness about benefits of CD antigen therapy: There is growing awareness among people about benefits of CD antigen therapy over traditional chemotherapy drugs, which is propelling the growth of this market. Moreover, increasing investment by key players in research and development activities for novel CD antigen therapies are also fuelling the growth of this market.
- Technological advancements: The technological advancements in diagnosis and treatment procedures are providing impetus to the growth if CD antigen therapy market as they are helping in early detection and treatment o cancers patients at an early stage when cure rates are high with minimal side effects associated with them .This is resulting into increased adoption rateofCDantigencancertherapiesamongpatientsleadingtomoregrowthforthemarketinfutureperiods .
Scope Of The Report
Report Attributes
Report Details
Report Title
CD Antigen Cancer Therapy Market Research Report
By Type
Monoclonal Antibodies, Antibody-Drug-Conjugates, Tri-Functional and Bi-Specific T-Cell Engager Antibodies, Other
By Application
Hospitals, Clinics, Other
By Companies
AryoGen Biopharma, Biocad, Biogen Idec, Celltrion, Genentech, Genmab, GLYCART Biotechnology, Hetero Drugs, mAbxience, MedImmune, Merck, Sandoz, UCB
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global CD Antigen Cancer Therapy Market Report Segments:
The global CD Antigen Cancer Therapy market is segmented on the basis of:
Types
Monoclonal Antibodies, Antibody-Drug-Conjugates, Tri-Functional and Bi-Specific T-Cell Engager Antibodies, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AryoGen Biopharma
- Biocad
- Biogen Idec
- Celltrion
- Genentech
- Genmab
- GLYCART Biotechnology
- Hetero Drugs
- mAbxience
- MedImmune
- Merck
- Sandoz
- UCB
Highlights of The CD Antigen Cancer Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Antibody-Drug-Conjugates
- Tri-Functional and Bi-Specific T-Cell Engager Antibodies
- Other
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CD Antigen Cancer Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CD antigen cancer therapy is a new form of cancer treatment that uses the patient's own immune system to fight the cancer. The therapy works by using specially designed vaccines to help the body recognize and attack tumor cells.
Some of the key players operating in the cd antigen cancer therapy market are AryoGen Biopharma, Biocad, Biogen Idec, Celltrion, Genentech, Genmab, GLYCART Biotechnology, Hetero Drugs, mAbxience, MedImmune, Merck, Sandoz, UCB.
The cd antigen cancer therapy market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. CD Antigen Cancer Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. CD Antigen Cancer Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. CD Antigen Cancer Therapy Market - Supply Chain
4.5. Global CD Antigen Cancer Therapy Market Forecast
4.5.1. CD Antigen Cancer Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. CD Antigen Cancer Therapy Market Size (000 Units) and Y-o-Y Growth
4.5.3. CD Antigen Cancer Therapy Market Absolute $ Opportunity
5. Global CD Antigen Cancer Therapy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. CD Antigen Cancer Therapy Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies
5.3.2. Antibody-Drug-Conjugates
5.3.3. Tri-Functional and Bi-Specific T-Cell Engager Antibodies
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global CD Antigen Cancer Therapy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. CD Antigen Cancer Therapy Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global CD Antigen Cancer Therapy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. CD Antigen Cancer Therapy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global CD Antigen Cancer Therapy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. CD Antigen Cancer Therapy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global CD Antigen Cancer Therapy Demand Share Forecast, 2019-2026
9. North America CD Antigen Cancer Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America CD Antigen Cancer Therapy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America CD Antigen Cancer Therapy Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America CD Antigen Cancer Therapy Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies
9.7.2. Antibody-Drug-Conjugates
9.7.3. Tri-Functional and Bi-Specific T-Cell Engager Antibodies
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America CD Antigen Cancer Therapy Demand Share Forecast, 2019-2026
10. Latin America CD Antigen Cancer Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America CD Antigen Cancer Therapy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America CD Antigen Cancer Therapy Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America CD Antigen Cancer Therapy Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies
10.7.2. Antibody-Drug-Conjugates
10.7.3. Tri-Functional and Bi-Specific T-Cell Engager Antibodies
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America CD Antigen Cancer Therapy Demand Share Forecast, 2019-2026
11. Europe CD Antigen Cancer Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe CD Antigen Cancer Therapy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe CD Antigen Cancer Therapy Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe CD Antigen Cancer Therapy Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies
11.7.2. Antibody-Drug-Conjugates
11.7.3. Tri-Functional and Bi-Specific T-Cll Engager Antibodies
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe CD Antigen Cancer Therapy Demand Share, 2019-2026
12. Asia Pacific CD Antigen Cancer Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific CD Antigen Cancer Therapy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific CD Antigen Cancer Therapy Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific CD Antigen Cancer Therapy Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies
12.7.2. Antibody-Drug-Conjugates
12.7.3. Tri-Functional and Bi-Specific T-Cell Engager Antibodies
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific CD Antigen Cancer Therapy Demand Share, 2019-2026
13. Middle East & Africa CD Antigen Cancer Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa CD Antigen Cancer Therapy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa CD Antigen Cancer Therapy Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa CD Antigen Cancer Therapy Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies
13.7.2. Antibody-Drug-Conjugates
13.7.3. Tri-Functional and Bi-Specific T-Cell Engager Antibodies
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa CD Antigen Cancer Therapy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global CD Antigen Cancer Therapy Market: Market Share Analysis
14.2. CD Antigen Cancer Therapy Distributors and Customers
14.3. CD Antigen Cancer Therapy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AryoGen Biopharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biocad
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biogen Idec
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celltrion
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genentech
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Genmab
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GLYCART Biotechnology
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hetero Drugs
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. mAbxience
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. MedImmune
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Merck
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sandoz
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. UCB
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
